mPGES-1 Inhibitor Therapy for Chronic Prostatitis Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective therapeutic methods for chronic prostatitis/chronic pelvic pain syndrome, as the etiology of this condition is not well understood, and existing treatments do not adequately address the underlying pathophysiology.
Innovation Solution
Development of a prophylactic and therapeutic agent containing an mPGES-1 inhibitor, specifically compounds of Formula [1] or their pharmaceutically acceptable salts, to target the mPGES-1 pathway, reducing pain and inflammation in animal models of chronic prostatitis/chronic pelvic pain syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for chronic prostatitis/chronic pelvic pain syndrome, then general symptoms may be managed, but the underlying inflammation and pain pathways are not effectively targeted
Solution Approach 1:
The patent applies parameter changes by targeting a specific biochemical parameter (mPGES-1 enzyme activity) rather than using broad-spectrum treatments. The mPGES-1 inhibitor selectively modulates the PGE2 synthesis pathway, changing the therapeutic parameter from general anti-inflammatory effects to specific prostaglandin E2 pathway inhibition, thereby improving therapeutic reliability for chronic prostatitis/chronic pelvic pain syndrome
Solution Approach 2:
The mPGES-1 inhibitor acts as an intermediary substance that blocks the conversion of PGH2 to PGE2 by inhibiting the mPGES-1 enzyme. This intermediary approach allows selective intervention in the inflammatory pathway without directly affecting other physiological processes, resolving the contradiction between effective symptom management and treatment complexity
2Adaptability or versatility
If the etiology of chronic prostatitis/chronic pelvic pain syndrome is not well understood, then targeted therapies cannot be developed, but this lack of understanding prevents effective treatment development
Solution Approach 1:
The patent applies preliminary action by proactively identifying and targeting the mPGES-1 pathway based on emerging understanding of its role in inflammation and cancer. Rather than waiting for complete etiological clarification, the invention takes preliminary therapeutic action by blocking a key enzyme in the PGE2 synthesis pathway that is upregulated in chronic prostatitis, thereby enabling treatment development despite incomplete etiological knowledge
Solution Approach 2:
The invention changes the therapeutic parameter from empirical symptom management to mechanism-based targeted therapy by identifying mPGES-1 as a key player in the disease pathology. This parameter change enables treatment adaptability to specific molecular pathways involved in chronic prostatitis/chronic pelvic pain syndrome
Data Source
AI summary
The present invention relates to a prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome, the agent containing an mPGES-1 inhibitor as an active ingredient.